Aprea Highlights Encouraging Phase 1 Data for APR-1051

Aprea Therapeutics ( (APRE) ) has shared an update.

On February 18, 2026, Aprea Therapeutics reported additional preliminary data from its ongoing first-in-human Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in advanced solid tumors, highlighted by a second unconfirmed partial response in a patient with advanced endometrial cancer at the 220 mg dose. The patient, whose tumor carries a PPP2R1A mutation, showed 50% tumor shrinkage and an 87% drop in CA-125 with only Grade 1 adverse events, contributing to a dataset that now includes two unconfirmed partial responses, five cases of stable disease, and generally favorable tolerability, supporting the drug’s potential in genomically defined, difficult-to-treat cancers and guiding further enrollment in PPP2R1A-mutated endometrial and HPV-positive head and neck cancer cohorts.

The ACESOT-1051 study has treated 22 patients across doses from 10 mg to 220 mg, with unconfirmed partial responses seen at 150 mg and 220 mg in endometrial cancers harboring PPP2R1A mutations and stable disease observed in multiple tumor types including colon, uterine and head and neck cancers. These emerging signals of anti-tumor activity without class-limiting toxicity bolster Aprea’s strategy to differentiate APR-1051 through an improved therapeutic index and underpin planned trial expansion and further data updates expected later in 2026.

The most recent analyst rating on (APRE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.

Spark’s Take on APRE Stock

According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.

APRE scores low primarily due to weak financial performance (ongoing losses and cash burn with declining revenue) and bearish technicals (trading below key moving averages with negative MACD). Valuation provides limited support given negative earnings and no dividend yield data.

To see Spark’s full report on APRE stock, click here.

More about Aprea Therapeutics

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that exploit vulnerabilities created by cancer-specific genetic mutations while sparing healthy cells. Its lead programs include APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, targeting solid tumors such as ovarian, endometrial, colorectal and head and neck squamous cell carcinoma.

Average Trading Volume: 2,074,800

Technical Sentiment Signal: Sell

Current Market Cap: $4.26M

For an in-depth examination of APRE stock, go to TipRanks’ Overview page.